Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
- Associated Therapies
- -
TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 72
- Registration Number
- NCT00164463
- Locations
- 🇺🇬
Makerere University Medical School, Kampala, Uganda
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2011-08-03
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 433
- Registration Number
- NCT00144417
- Locations
- 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇺🇸University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸University of California at San Diego, San Diego, California, United States
Tuberculosis Treatment Shortening Trial
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 394
- Registration Number
- NCT00130247
- Locations
- 🇧🇷
Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
🇺🇬Mulago Hospital Complex, Kampala, Uganda
🇵🇭Makati Medical Center, Makati, National Capital Region, Philippines
A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- Medical Research Council Unit, The Gambia
- Target Recruit Count
- 214
- Registration Number
- NCT00130325
- Locations
- 🇬🇲
MRC Laboratories, Banjul, Ksmd, Gambia
Treatment of Latent TB Infection for Jailed Persons
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 364
- Registration Number
- NCT00128206
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Tuberculosis Prevention for HIV Infected Adults
- Conditions
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2012-10-22
- Target Recruit Count
- 1148
- Registration Number
- NCT00057122
- Locations
- 🇿🇦
Chris Hani Baragwanath Hospital, Soweto, South Africa
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 150
- Registration Number
- NCT00023348
- Locations
- 🇺🇸
Denver Department of Public Health and Hospitals, Denver, Colorado, United States
🇺🇸Hines VA Medical Center, Hines, Illinois, United States
🇨🇦University of Manitoba, Winnipeg, Manitoba, Canada
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 36
- Registration Number
- NCT00023387
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
- Conditions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1000
- Registration Number
- NCT00023335
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.